Frontline drug treatment for newly diagnosed B-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a combination of targeted and chemotherapy medicines as first treatment for newly diagnosed B-cell acute lymphoblastic leukemia (ALL) or related lymphoblastic lymphoma. It aims to improve how well treatment controls the leukemia and how long people can stay in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed (untreated) B-cell ALL or lymphoblastic lymphoma, or you just got complete remission after one induction chemo course
- You can receive helpful medicines like steroids or (ara-C or Hydrea) before the final treatment plan is set
- You are able to do daily activities fairly well (performance status 0 to 3)
- Your kidneys and liver blood tests are not too high (creatinine ≤ 2.0 mg/dL and bilirubin ≤ 2.0)
- You are not pregnant or breastfeeding, and you can sign the consent form
- You do not have certain brain/CNS conditions (like seizures or stroke history) caused by other illnesses
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a combination of a targeted drug and low-dose chemotherapy for adults newly diagnosed with a certain type of acute lymphoblastic leukemia (ALL). The goal is to find a gentler but effective treatment that may be easier for patients to tolerate.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
Hear when a new B Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.